Fig. 2: S2172 affected H3K4me2 modifications. | Cancer Gene Therapy

Fig. 2: S2172 affected H3K4me2 modifications.

From: Novel pharmacologic inhibition of lysine-specific demethylase 1 as a potential therapeutic for glioblastoma

Fig. 2

A Western blot analysis of H3K4me1, H3K4me2, H3K4me3, H3K9me2, and H3 after treatment with either DMSO or S2172 (5 μM) for 96 h in GSC1228, GSC222, and GSC316. Histone H3 was used as the loading control. B Quantification of band signal intensities from the western blot of A. The y-axis in the panel indicates relative signal intensity of each protein normalized to histone H3. Error bars indicate the SD. C Upper panel, ChIP-seq peaks (3 kb upstream and downstream of the H3K4me2-binding site) of H3K4me1, H3K4me2, H3K4me3 and H3K9me2. Signal intensity is shown on the right. Lower panel, Distribution of H3K4me2 and H3K4me3 signals at H3K4me2-binding site in GSC1228 treated with DMSO or S2172 (5 μM). D Peaks of H3K4me1, H3K4me2, H3K4me3 were identified using HOMER findPeaks function with histone setting. Venn diagrams for each binding peak are shown. E Distribution of H3K4me2 peaks at the ‘increased’ and ‘de novo’ regions. F Representative ChIP-seq peaks at the MYC and Nestin loci.

Back to article page